A CASE REPORT AND ROLE OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF IMMUNE - MEDIATED NECROTIZING MYOSITIS
DOI:
https://doi.org/10.59459/1859-1655/JMM.840Từ khóa:
Immune mediated necrotizing myopathy, intravenous immunoglobulin, myositisTóm tắt
Objective: To report a rare case of idiopathic autoimmune myopathy that was successfully managed with intravenous immunoglobulin (IVIG) therapy.
Methods: We described the clinical course, diagnostic workup, and therapeutic response of a patient definitively diagnosed with IMNM at the 108 Military Central Hospital.
Results: A 62-year-old male presented with symmetrical proximal muscle weakness and markedly elevated creatine kinase (CK) levels (> 9,000 U/L). Serological testing was positive for anti-signal recognition particle (anti-SRP) antibodies, and muscle biopsy confirmed myofibre necrosis consistent with IMNM. Initially, the patient was treated with high-dose corticosteroids combined with mycophenolate mofetil, which resulted in poor response and progressive worsening of muscle weakness. Subsequent adjunctive therapy with IVIG (2 g/kg body weight was administered over 5 days, repeated after one month), along with optimized immunosuppression resulted in significant clinical improvement in muscle strength, restored mobility, CK levels and no significant adverse effects were observed during the treatment period.
Conclusion: Intravenous immunoglobulin is an effective and well-tolerated therapeutic intervention for immune-mediated necrotizing myopathy, particularly in cases refractory to standard treatment.
Tài liệu tham khảo
1. Li C, Liu H, Yang L, Liu R, Yin G, Xie Q, “Immune-mediated necrotizing myopathy: A comprehensive review of the pathogenesis, clinical features, and treatments”, Journal of Autoimmunity, 148:103286, 2024.
2. Pinal-Fernandez I, Casal-Dominguez M, Mammen A.L, “Immune-Mediated Necrotizing Myopathy”, Current rheumatology reports, 20 (4): 21, 2018.
3. Chan E.K.L, “Anti-Ro52 Autoantibody is common in systemic autoimmune rheumatic diseases and correlating with worse outcome when associated with interstitial lung disease in systemic sclerosis and autoimmune myositis”, Clinical reviews in allergy & immunology, 63 (2): 178-93, 2022.
4. Mulcahy K.P, Langdon P.C, Mastaglia F, “Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence”, Dysphagia. 27 (1): 64-9, 2012.
5. Oh T.H, Brumfield K.A, Hoskin T.L, Stolp K.A, Murray J.A, Bassford J.R, “Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients”, Mayo Clinic proceedings, 82 (4): 441-7, 2007.
6. Dalakas M.C, “Intravenous immunoglobulin in autoimmune neuromuscular diseases”, JAMA, 291 (19): 2367-75, 2004.
7. Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, et al., “Necrosis in anti-SRP (+) and anti-HMGCR (+) myopathies: Role of autoantibodies and complement”, Neurology, 90 (6): e507-e17, 2018.
8. Meyer A, Scirè CA, Talarico R, Alexander T, Amoura Z, Avcin T, et al., Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines (corrected), RMD open. 4 (Suppl 1): e000784, 2018.
9. Needham M, Mastaglia F.L, “Immunotherapies for Immune-Mediated Myopathies: A Current Perspective”, Neurotherapeutics: the journal of the American Society for Experimental Neuro Therapeutics, 13 (1): 132-46, 2016.
10. Rotella K, Rodriguez Alvarez M, Saperstein Y, Bhamra M, Zhaz Leitner S, Feoktistov A, et al., “Tacrolimus-Induced Remission in Drug Resistant Inflammatory Myopathy: A Case Series”, Rheumatology: Current Research, 08, 2018.
11. Mammen AL, Tiniakou E. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. The New England journal of medicine, 373 (17): 1680-2, 2015.
12. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L, “Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series”, Arthritis care & research, 62 (9): 1328-34, 2010.
Tải xuống
Đã Xuất bản
Cách trích dẫn
Số
Chuyên mục
Ngày xuất bản 31-05-2026
